SBC

Business Context and Reporting Period

Company: SBC Medical Group Holdings Inc (SBC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: SBC provides comprehensive management services to medical corporations and clinics, primarily in Japan, under the "Shonan Beauty Clinic" brand. Services include franchising, procurement, management consulting, and rental services. The company operates two reportable segments: SBC Core and Waqoo (acquired Dec 2025, consolidated with a 3-month lag).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth (QTD): Revenue increased 13.4% to $49.19 million compared to $43.36 million in Q2 2025. This was driven by the inclusion of the Waqoo Segment ($4.51 million) and a 150% increase in Management Services revenue, partially offset by declines in Franchising and Procurement revenue due to JPY depreciation and lower equipment rental demand.
• Profitability (QTD): Net income attributable to SBC surged 335% to $10.69 million from $2.46 million in Q2 2025. The effective tax rate dropped to 40.0% from 82.0% in the prior year, as the prior period included a significant one-time tax expense related to a deemed contribution.
• Profitability (YTD): Net income attributable to SBC decreased 8.2% to $22.00 million from $23.96 million in the first half of 2025. This decline was primarily due to the absence of an $8.75 million gain on the redemption of life insurance policies recorded in H1 2025.
• Cash Flow: Operating cash flow turned positive at $31.74 million for the six months ended June 30, 2026, compared to a use of $6.41 million in the same period in 2025.

Guidance, Outlook, and Risks

• Recent Developments: In April 2026, the Company completed a secondary public offering of 3.57 million shares sold by the CEO; the Company incurred $1.4 million in transaction costs but received no proceeds. Effective June/July 2026, fee revisions with medical corporations are expected to increase annualized management service revenue by approximately $15 million.
• Investment Commitment: The Company has committed to an additional $5 million cash investment in OT Midco Holdings, LLC, payable in December 2026.
• Legal Proceedings: A stockholder class action was filed in February 2026 regarding director removal provisions. Stockholders approved amendments to the certificate of incorporation in July 2026 to address the complaint. The Company cannot estimate a range of loss.
• Nasdaq Compliance Risk: As of July 8, 2026, the Company ceased to satisfy Nasdaq independence requirements for its board of directors. It has received a cure period until July 9, 2027, to regain compliance. Failure to do so could result in delisting.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2026, due to previously identified material weaknesses that remain un-remediated.
• Foreign Exchange: The depreciation of the Japanese Yen against the U.S. Dollar negatively impacted reported revenues and net income by approximately $4.75 million and $1.32 million, respectively, for the quarter.

Investor Verification Checklist

• Related Party Transactions: Verify the arm's-length nature of transactions, as approximately 88% of Q2 2026 revenue ($43.73 million) was derived from related parties (Medical Corporations controlled by the CEO's relatives).
• Internal Control Remediation: Monitor progress on the remediation plan for material weaknesses in internal controls over financial reporting, which currently render disclosure controls ineffective.
• Nasdaq Listing Status: Track the Company's efforts to appoint an additional independent director to cure the Nasdaq non-compliance notice received in July 2026.
• FX Sensitivity: Assess the impact of continued JPY volatility on future earnings, given the majority of operations are in Japan.
• OT Midco Investment: Confirm the timing and terms of the committed $5 million additional investment in OT Midco.